Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 281 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo 50 or 100 mg Clear all
Terminated Phase 2Phase 3 Interventional Results available

Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain

NCT04356352
View directory record Official record
Conditions
Injection Site Irritation, Pain
Interventions
Lidocaine, Esmolol, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 2 Interventional Results available

Study Effect of VIA-2291 on Vascular Inflammation

NCT00358826
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
VIA-2291, Placebo
Drug
Lead sponsor
Tallikut Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Melbourne, Florida • Minneapolis, Minnesota • Tupelo, Mississippi + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine

NCT02828020
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Ubrogepant, Placebo-matching Ubrogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
90
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 1 Interventional

Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis

NCT02049203
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Ataciguat, Placebo
Drug
Lead sponsor
Jordan D. Miller, Ph.D.
Other
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 2 Interventional Results available

Vitamin C & Thiamine to Treat Sepsis and Septic Shock

NCT03592277
View directory record Official record
Conditions
Sepsis, Septic Shock
Interventions
Vitamin C, Vitamin B1
Drug
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

NCT03082235
View directory record Official record
Conditions
Healthy Participants
Interventions
E6742, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 14, 2026, 7:53 AM EDT
Withdrawn Phase 3 Interventional

Gabapentin and Chronic Post Surgical Pain

NCT03867240
View directory record Official record
Conditions
Pain, Postoperative, Scoliosis Idiopathic
Interventions
Gabapentin, Placebo
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
10 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients

NCT00001082
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Levocarnitine, Adefovir dipivoxil, Adefovir dipivoxil placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 14, 2026, 7:53 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

NCT00298272
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate
Biological · Drug · Dietary Supplement
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
18
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 3 Interventional

Treatment of Erectile Dysfunction - Long Term Safety and Efficacy

NCT01065012
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Udenafil 50 mg, Udenafil 100 mg, Udenafil 150 mg, Placebo Matching 50 mg Udenafil, Placebo Matching 100 mg Udenafil, Placebo Matching 150 mg Udenafil
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
19 Years and older · Male only
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
72
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 65 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Not applicable Interventional Results available

Quetiapine for the Reduction of Cocaine Use

NCT00631748
View directory record Official record
Conditions
Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Drug Abuse, Substance Abuse
Interventions
quetiapine fumarate, Matched Placebo, Cognitive-behavioral Therapy
Drug · Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 4 Interventional Results available

Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation

NCT02796755
View directory record Official record
Conditions
Inflammation, Fatigue
Interventions
Riluzole, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 2 Interventional Results available

A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo

NCT01359150
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
51
States / cities
Gilbert, Arizona • Paradise Valley, Arizona • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 3 Interventional

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

NCT00605683
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Safinamide (as add-on therapy)
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
30 Years to 80 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oxnard, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 2 Interventional Results available

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

NCT03084536
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Cancer of Breast
Interventions
Bupivacaine, Gabapentin, Celecoxib, Acetaminophen, Midazolam, Fentanyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 14, 2026, 7:53 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia

NCT01328002
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
13 Years to 17 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
47
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Fresno, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 2 Interventional Results available

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

NCT01970501
View directory record Official record
Conditions
Current or Recent History of Atrial Fibrillation
Interventions
bucindolol hydrochloride, metoprolol succinate, Placebo oral capsule
Drug · Other
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
48
States / cities
Anchorage, Alaska • Phoenix, Arizona • East Palo Alto, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban

NCT02207257
View directory record Official record
Conditions
Anticoagulation Reversal
Interventions
PER977, Placebo, Edoxaban
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Genotype on Resting State Connectivity During Methamphetamine Administration

NCT03973489
View directory record Official record
Conditions
Methamphetamine-dependence
Interventions
Magnetic resonance imaging (MRI), Methamphetamine Hydrochloride Tablets, Placebo oral tablet
Behavioral · Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003

NCT01856309
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Sirukumab 100 mg, Sirukumab 50 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
66
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 14, 2026, 7:53 AM EDT
Terminated Phase 2 Interventional Results available

A Study of LY2599506 in Patients With Type 2 Diabetes

NCT01024244
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, LY2599506
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Topeka, Kansas • Toms River, New Jersey • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2011 · Synced Oct 14, 2026, 7:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist

NCT03070730
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome, Orthostatic Intolerance
Interventions
Droxidopa, Atenolol, Placebos
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 14, 2026, 7:53 AM EDT
Completed Phase 3 Interventional

A New Sildenafil Oral Film in Patients With Erectile Dysfunction

NCT05490680
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg, Placebo
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
18 Years and older · Male only
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
18
States / cities
Foley, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 14, 2026, 7:53 AM EDT